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Nucleostemin (NS), a p53-binding protein, has been shown essential for stem and cancer cell proliferation and implicated in
oncogenesis. To explore potential contributions of NS to the development of clear cell renal cell carcinomas (ccRCCs), we
determined NS expression in ccRCC cell lines, and in paired normal and malignant renal tissues from 31 patients with ccRCC.
Nucleostemin mRNA and/or protein expression was observed in all four cell lines and 27 of 31 (87%) tumour specimens.
Surprisingly, 16 of 31 (52%) adjacent normal renal samples also expressed NS mRNA and its levels in four of them were comparable
with those in paired tumour tissues. Three of the patients had detectable NS mRNA in their normal renal tissues whereas lacked its
expression in the matched tumours. Compared to the oncogene c-MYC expression in these same samples, NS expression showed a
much less specificity for ccRCC. We further demonstrated that NS mRNA expression was closely associated with cellular
proliferation in normal fibroblasts or T lymphocytes and renal cell carcinoma cell lines. Collectively, NS expression widely occurs in
normal and malignant renal tissues, and is likely a proliferation marker rather than a unique regulator of cell proliferation and survival in
stem and cancer cells.
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Renal cell carcinoma (RCC), the most common malignant tumour
of the adult kidney in both developed and developing countries,
accounts for 2–3% of all human malignancies with close to 100000
yearly deaths worldwide (Whang and Godley, 2003; Lam et al,
2005; Patel et al, 2006). As a pathologically and genetically
heterogeneous disease, RCC falls into at least four subtypes,
including clear-cell, a predominant type (about 80%) and others
(papillary, chromophobe, and collecting duct carcinomas). In clear
cell renal cell carcinoma (ccRCC), inactivation of the von Hippel–
Lindau disease tumour suppressor (VHL gene) by different
mechanisms is widespread and believed to be an early or a first
event during the oncogenic process (Foster et al, 1994; Gnarra
et al, 1994; Brauch et al, 2000; Linehan et al, 2004; Maher, 2004).
However, molecular mechanisms underlying the full development
of ccRCC are largely unknown. Clinically, approximately 30% of
patients with ccRCC present with widely disseminated diseases,
and even higher percentages of patients treated with complete
surgical resection undergo metastatic progression within a short
period (Glaspy, 2002; Pantuck et al, 2003; Whang and Godley,
2003; Lam et al, 2005; Patel et al, 2006). Moreover, recurrent
ccRCC responds poorly to the current biotherapy and chemo-
therapy (Donskov et al, 2006; Patel et al, 2006). Although a number
of molecular and clinical parameters have been shown as prog-
nostic markers for ccRCC (Campbell et al, 2003; Elmore et al, 2003;
Kallio et al, 2003; Schips et al, 2003; Thomas et al, 2003; Kallio
et al, 2004; Zigeuner et al, 2004; Dudderidge et al, 2005), the
clinical outcome of patients with ccRCC shows a broad variation.
Therefore, better defining the pathogenesis of ccRCC, looking for
reliable early diagnostic markers, and exploring novel intervention
targets for ccRCC are urgently demanding tasks.
One of the most important hallmarks for cancers is their
deregulated cellular proliferation. The aberrant activation of the
oncogene c-MYC, observed in many different types of human
cancers, has been implicated as a driving force for abnormal cell
growth (Nasi et al, 2001; Hermeking, 2003). More recently, a p53-
binding protein, named nucleostemin (NS) abundantly expressed
in stem and cancer cells but silenced in differentiated cells, has
been shown to be essential for stem and cancer cell proliferation
and survival (Tsai and McKay, 2002). It is currently unknown
whether this newly identified molecule is involved in ccRCC
pathogenesis. In the present study, we investigated NS mRNA
expression in both normal and malignant renal tissues, and
examined potential relationships between its expression and
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sclinico-pathological characteristics in ccRCC. Additionally, be-
cause NS shares certain similarities with the oncogene c-MYC in
terms of expression profile and functional properties (Nasi et al,
2001; Tsai and McKay, 2002), we further compared the NS
expression profile with the c-MYC activation in ccRCC.
PATIENTS AND METHODS
Cell lines and cell culture
Four ccRCC cell lines, A498, KRC/Y, CAKI-2, and TK10, were
maintained at 371C in Dulbecco’s modified Eagle’s medium (Life
Technologies, Paisley, UK) supplemented with 10% fetal calf serum
(FCS), 2mML -glutamine, 100Uml
 1 penicillin and streptomycin,
under 5% CO2/95% air. Cells at logarithmically growing phases
were harvested for reverse transcription–polymerase chain reac-
tion (RT–PCR) analyses of NS and c-MYC mRNA expression. To
determine the relationship between NS expression and cellular
proliferation, the cells were incubated in 0.2% FCS-containing
medium for 72h to induce quiescence and then re-fed with 20%
FCS for 24h. Normal T lymphocytes were isolated from the buffy-
coaded blood derived from normal individuals and treated with
15mg/ml ConA to stimulate their proliferation. Normal dermal
fibroblasts were kindly provided by Dr Z. Yan (Karolinska
Institute, Sweden).
Patients and tissue specimens
The ccRCC tumour samples and their adjacent normal renal
tissues were obtained from 31 patients with primary ccRCC. The
study was approved by the local ethics committee, and all the
patients consented to the use of their renal tissues for the present
investigation. The patients were treated with radical nephrectomy
at Qilu Hospital, Shandong University, between 2002 and 2003.
After surgery, the tumour specimens and adjacent normal renal
tissues were stored at  801C until use. For each ccRCC, tumour
size (diameter), Robson stage, and regional and distant metastases
at nephrectomy were evaluated by both pathologists and
urologists. Patient and disease information is listed in Table 1.
RNA extraction, reverse transcription, and polymerase
chain reaction
Total cellular RNA was extracted using the ULTRASPECt -II RNA
kit (Biotecx Lab., Houston, TX, USA). cDNA was synthesised using
random primers (N6) (Pharmacia, Uppsala, Sweden) and M-MLV
reverse transcriptase. The polymerase chain reaction (PCR) primer
sequences specific for NS mRNA (Accession number: AY825265)
were: 50-GAA ACA GAG GCT TGA AGA ACT AA (forward) and
50-GGA GGC TTC GAT CAC CTT TTT A (reverse). Polymerase chain
reaction was performed with the use of 32 amplification cycles
(951C for 1500,6 4 1C for 3000, and 721C for 3000) and the PCR product
was 223bp in length. The RT–PCR for the oncogene c-MYC
mRNA (Accession number: HSMYC1) was performed as described
(Garrett et al, 2002), and the primer sequences were: forward: TAC
CCT CTC AAC GAC AGC AGC TCG CCC AAG TCC T and reverse:
TCT TGA CAT TCT CCT CGG TGT CCG AGG ACC T, which led to
the amplification of a 479bp long DNA fragment. A total of 30 PCR
cycles at 951C for 1500,6 0 1C for 4500, and 721C for 6000 was carried
out. b-Actin expression was used as an internal control and
amplified with its specific primers using 25 cycles (Fan et al, 2005).
Polymerase chain reaction products were resolved in 2% agarose
gels, stained with ethidium bromide, and visualized in ultraviolet
light. The PCR conditions were optimised to make sure a linear
amplification of each target, and PCR results for NS and c-MYC
were recorded as negative ( ), moderate positive (þ), and
strongly positive (þþ) based on their signal intensities and
b-actin reference.
Western blot
Western blot was performed as described (Xu et al, 2000). Briefly,
total proteins were extracted with sodium dodecyl sulphate lysis
buffer, and 50mg of the proteins were resolved by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis and transferred to
an intracellulos membrane. The membranes were probed with
the specific primary antibody against NS (Cat# 14-86-42-80;
eBioscience, San Diego, CA, USA) followed by secondary anti-
rabbit horseradish peroxidase-conjugated IgG and developed with
the enhanced chemiluminescent method (ECL, Amersham, UK).
Immunohistochemistry
Immunohistochemical staining was performed as described earlier
(Zhang et al, 2000). Following deparaffinization, antigen unmask-
ing, and inactivation of endogenous peroxidase, the primary
antibody against NS (eBioscience, San Diego, CA, USA) was 1:10
diluted, added onto slides, and incubated at 41C overnight. An
antibody binding was visualised by using the secondary antibodies
conjugated with horseradish peroxidase and an AEC kit according
to the manufacturers’ protocols (Dako Corporation, Denmark).
The slides were finally counterstained with haematoxylin. Cover-
slips were mounted onto glass slides and examined with a light
microscope equipped with a CCD camera (Nikon, Eclipse E800,
Japan).
Table 1 Patients’ characteristics, nucleostemin, and c-MYC mRNA
expression in ccRCCs and adjacent normal renal tissues
Clinical/pathological information Tumours Normal tissues
Patient
Age/
gender
Sizes
(cm) Stages NS
a c-MYC
a NS c-MYC
1 56/M 5.0 I + ++   +
2 54/F 4.5 I ++ + + +
3 56/M 5.5 I ++ ++   
4 52/M 8.0 I   +++
5 47/F 7.5 I + ++   
6 54/F 6.0 I   ND
2 +N D
7 54/F 10.0 I ++ +   
8 64/M 8.0 I   +   
9 68/F 4.5 I ++ ++   
10 57/M 6.5 I + ++   
11 76/M 5.0 I + + +  
12 44/M 2.5 I ++ ++   
13 62/M 3.0 I + +   
14 48/F 3.0 I ++ ++ +  
15 74/M 3.0 I ++ ++ + +
16 57/F 4.0 I ++ ++ +  
17 51/M 3.0 I + + + +
18 68/M 6.0 I ++ +   
19 79/F 3.0 I ++ ++ +  
20 36/M 6.5 I ++ +   
21 48/F 8.0 I ++ ++ +  
22 43/M 4.5 I + ++ +  
23 63/M 4.5 I + +   
24 39/F 5.0 II + + + +
25 48/M 8.0 II ++ ++ +  
26 68/M 10.5 II
Mb ++ ND   ND
27 69/M 8.0 II
M ++ ++   
28 64/M 8.0 III
M ++ ++ + +
29 54/M 12.5 IV
M   ++ 
30 28/F 15.5 IV
M ++ ++ + +
31 64/M 7.0 IV
M ++   
ccRCCcs¼clear cell renal cell carcinomas; ND¼not done; NS¼nucleostemin;
PCR¼polymerase chain reaction.
aPCR results for NS and c-MYC were recorded as
negative ( ), moderate positive (+), and strongly positive (++) based on their signal
intensities.
bM: With metastasis.
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NS mRNA and protein expression in ccRCC cell lines
We first examined NS mRNA and protein in cultured ccRCC cell
lines. For this purpose, A498, KRC/Y, CAKI-2, and TK10 cells were
used and all the four cell lines contained NS mRNA, as determined
by using RT–PCR (Figure 1A, left panel). The result demonstrated
that ccRCC tumour-derived cells, like other types of human cell
lines reported previously, exhibited a transcriptional activation
of the NS gene. Consistent with its mRNA expression, NS protein
was readily detectable in all these cell lines with the use of an
immunoblotting assay (Figure 1A, right panel).
NS mRNA and protein expression in primary ccRCC
specimens
We next carried out NS mRNA analyses in primary ccRCC
samples. A total of 31 tumours obtained from 31 patients with
ccRCC were examined and NS mRNA detected in 27 of them (86%,
Table 1, Figure 1B and C). Compared to the cell lines, those
primary tumours had largely similar levels of NS mRNA. More-
over, we further performed immunohistochemical analyses on 10
available tumour specimens to examine NS protein expression.
Nine of 10 examined patient tumours exhibited a positive staining
for NS in more than 20% cells and in all the positive specimens, NS
was observed in both cytoplasmic and nuclear compartments of
tumour cells (Figure 2). This distribution profile of NS was very
similar to that found in gastric cancers (Yang et al, 2005). The
staining intensity of the NS protein was in general consistent with
its mRNA expression in the examined tumour specimens.
We then compared NS expression with clinico-pathological
parameters, and found no significant associations between the
presence of NS mRNA and patients’ age, gender, tumour sizes,
disease stages, and metastases.
Detectable NS mRNA expression in more than half of
adjacent normal renal tissues
We then wanted to ask whether transcriptional activation of the NS
gene also occurred in normal renal cells. The adjacent normal renal
samples from these 31 patients were analysed for NS mRNA
expression, and unexpectedly, 16 of them (51%) expressed
detectable NS mRNA (Table 1 and Figure 1C). Of these NS-
expressing normal samples, the levels of NS mRNA in nine cases
were lower than in their paired tumours and in four patients were
comparable with their tumour counterparts. Intriguingly, it was
observed in three patients that NS mRNA was only present in their
normal renal tissues whereas absent in their tumour specimens
(Table 1, patients 4, 6, and 29). Taken together, NS mRNA is
expressed in normal human renal tissues with a high frequency.
A close relationship between NS expression and cell
proliferation in normal human cells and ccRCC cells
To determine whether other kinds of normal cells express NS, we
analysed NS mRNA in normal human T lymphocytes and dermal
fibroblasts. As shown in Figure 1D, NS mRNA was readily
NS
C-MYC
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Figure 1 Nucleostemin expression in normal and malignant renal tissues
and other types of normal human cells. (A) Nucleostemin mRNA (left
panel) and protein (right panel) expression in ccRCC cell lines. Lane 1:
A498 cells; 2: TK10; 3: KRY/C, and 4: Caki2. (B) and (C) NS and c-MYC
mRNA expression in ccRCC samples and their adjacent normal renal
tissues. (D) Nucleostemin mRNA expression in normal human fibroblasts,
T lymphocytes, and A498 cells and relationship with cell proliferation
statuses. Lanes 1 and 2: normal fibroblasts at senescence and at early
passage, respectively. Lanes 3 and 4: normal resting and activated T
lymphocytes, respectively. Lane 5: ccRCC A498 cells with serum-starvation
for 72h. Lane 6: A498 cells undergoing 72h serum-starvation were re-fed
with 20% serum for 24h.
Figure 2 Immunohistochemical analyses for NS protein expression in tumour specimens derived from patients with ccRCC. Representative positive (A)
and negative (B) stainings are shown.
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lymphocytes activated by ConA expressed higher NS mRNA than
did the resting cells, and that senescent fibroblasts had lower
abundances of NS mRNA compared to the cells at early passages.
The above result suggests that NS may be a universal
proliferation marker rather than a specific regulator for prolifera-
tion of undifferentiated stem and cancer cells. To test this
hypothesis, we examined the kinetic changes in ccRCC cell lines
at quiescent and actively proliferating phases. We first induced
quiescence of A498 cells by maintaining them in 0.2% of FCS for
72h and then stimulated their proliferation by transferring them
into 20% FCS-containing medium. The RT–PCR analyses clearly
demonstrated significant downregulation of NS expression in G0
cells, but increased NS mRNA abundance following re-entry into
cell cycle (Figure 1D).
The oncogene c-MYC expression in normal and cancerous
renal tissues
We finally analysed c-MYC mRNA expression in this same set of
patients’ specimens. c-MYC mRNA was found in all 29 examined
tumour samples. Twenty-one of 29 adjacent normal renal tissues
lacked detectable c-MYC mRNA (Table 1 and Figure 1B). Although
eight of those normal samples expressed c-MYC mRNA, the
expression level was much lower compared to that in their paired
tumour tissues. We found no associations between NS and c-MYC
expression in both normal and malignant renal tissues, indicating
independent transcriptional regulation of two genes.
DISCUSSION
Tsai and McKay (2002) have recently identified NS, a novel
p53-binding protein that is abundantly present in stem cells and
stem cell-enriched tissues. Interestingly, both NS mRNA and
protein are absent in adult differentiated cells/tissues, although
highly expressed in different human cancer cell lines (Tsai and
McKay, 2002). Depletion of NS inhibits cell proliferation in both
stem and cancer cells, indicating its functional importance in
maintaining cell cycle progression of those cells. Prompted by
these interesting findings, we set out to investigate whether NS
has roles in RCC development, and if so, whether this molecule can
serve as a diagnostic marker or therapeutic target for RCC.
In the present study, we observed NS expression in all four
examined ccRCC cell lines and in 27 of 31 primary tumours,
suggestive of its widespread in primary ccRCC, consistent with
that seen in human cancer cell lines. Surprisingly, more than the
half of adjacent normal renal specimens also contained NS mRNA,
and the expression level in four of them was comparable with their
paired tumour tissues. In three patients, NS mRNA was present in
their normal renal tissues but absent in their tumours. Moreover,
we have similarly observed that both normal and cancerous
prostate tissues expressed rather high levels of NS mRNA (X Fang,
P Ekman, and D Xu, unpublished data). These unexpected findings
challenge the early concept of NS being a specific player for stem
and cancer cell proliferation. However, one may argue that (1)
tumour cell contamination in adjacent normal renal tissues may
contribute to detectable NS mRNA expression, as seen here.
However, these same specimens have previously been used for
analyses of telomerase activity and full-length of telomerase
reverse transcriptase mRNA expression, highly specific markers
for transformed cells, and both markers were exclusively absent in
all the studied adjacent normal tissues (Fan et al, 2005), which
suggests the lack of contaminated tumour cells in the normal
samples used in this study. (2) The stem cells present in kidneys
and prostates may be a source of NS mRNA. However, stem cells
in somatic tissues kidneys and prostates are in a rather low
number, and are unlikely a major contributor to the observed NS
expression in these organs. Our further identification of NS mRNA
expression in purified T lymphocytes and fibroblasts strongly
indicate that many types of differentiated human cells, if not all, do
express NS transcripts. Taken together, we conclude that NS
expression is not a unique feature for ccRCC and prostate cancers,
neither for stem cells.
According to our preliminary data, NS expression is prolifera-
tion-regulated and induced in actively cycling cells such as
presenescent human fibroblasts and activated T lymphocytes. On
the other hand, in vitro cultured RCC cells undergo down-
regulation of NS expression in response to serum starvation.
Regardless being stem cells, cancer cells, or normal differentiated
cells, they may all acquire NS expression when in actively
proliferating status. Therefore, NS is more like a proliferation
marker rather than a molecule only involved in the cell cycle
control of stem and cancer cells. This proposal provides a
reasonable explanation for what have been seen in normal renal
and prostate tissues: detectable NS transcript in them is virtually
expressed by proliferative epithelial or other types of cells; and
NS-expressing stem cells are negligible owing to their very low
numbers.
In normal stem cells and U2OS cells, NS protein was exclusively
localised in nucleus (Tsai and McKay, 2002). However, the primary
ccRCC tumour cells examined here exhibited both cytoplasmic and
nuclear localisations of NS, although a nuclear compartment with a
stronger signal. This distribution pattern of NS has recently been
observed in gastric cancers, too (Yang et al, 2005). It is currently
unclear how and why such a cytoplasmic localization occurs,
which calls for further investigations.
The oncogene c-MYC plays a key role in regulating cell
proliferation and its aberrant activation contributes to the
pathogenesis of many human malignancies including RCC (Nasi
et al, 2001). From expression and functional points of view, c-MYC
and NS share certain similarities: (1) both are abundantly present
in stem cells and downregulated in differentiated cells and (2) their
expression levels should be within a limited window, and both
depletion and overexpression lead to cell growth arrest and/or
apoptosis. Thus, we determined NS and c-MYC mRNA expression
in parallels. c-MYC mRNA was expressed in all 29 tumours
examined, whereas lower or comparable levels of c-MYC expres-
sion was only observed in 8/29 normal renal samples. Compared to
NS, c-MYC is a more specific marker for ccRCC.
The study presented herein demonstrates that NS is widely
expressed in both ccRCC and adjacent normal renal tissues,
in sharp contrast with the recent report that NS is present in
stem and cancer cells whereas absent in differentiated adult tissues
(Tsai and McKay, 2002). Although the levels of NS expression
are higher in most tumours than their paired normal renal tissues,
there was no significant correlation between NS expression
and patients’ clinico-pathological characteristics. Compared to the
c-MYC oncogene, NS expression shows less specificity for ccRCC,
and is unlikely to serve as a diagnostic marker and therapeutic
target for RCC. Our findings call for re-evaluation of the NS
expression profile in various normal human tissues, and
more rigorous delineation of its oncogenic role in human cell
transformation.
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